Morning Glory Sciences– Author –
After completing graduate school, I studied at a Top tier research hospital in the U.S., where I was involved in the creation of treatments and therapeutics in earnest. I have worked for several major pharmaceutical companies, focusing on research, business, venture creation, and investment in the U.S. During this time, I also serve as a faculty member of graduate program at the university.
-
Oncology Drug
KRAS Special Series Part 2: What Each Allele Tells Us — Biological and Clinical Diversity of G12D, G12V, G12R, and Q61
In Part 1, we traced the long struggle to target KRAS and the breakthrough that made the “undruggable” druggable. Now we turn to a crucial question: how do different KRAS alleles shape tumor biology, signaling behavior, and clinical outc... -
Oncology Drug
KRAS Special Series Part 1: The Rise, Fall, and Rebirth of the “Undruggable” Target
Few oncogenes have shaped the landscape of cancer research as profoundly as KRAS. Since the first RAS mutation was identified in human bladder cancer cells in 1982, this small GTP-binding protein has fascinated scientists as both a myste... -
Oncology Drug
Part 2|Inside AMPLIFY-201 Final Analysis: What the KRAS Vaccine Is Actually Moving
Takeaway: Lymph-node–targeted amphiphile delivery achieved robust dual CD4/CD8 responses. A data-driven ~9.17× immune threshold aligned with RFS/OS gains and ctDNA negativity in the adjuvant MRD setting. What you will learn Contents1. On... -
Oncology Drug
KRAS Cancer Vaccine Competitive Map: 4 Modalities Compared After Moderna/Merck V941’s Withdrawal
Takeaway: the field is coalescing around shared neoantigens × off-the-shelf × adjuvant MRD. Elicio (ELI-002 7P) leads the pack; academic SLP + poly-ICLC programs and Gritstone’s SLATE-KRAS follow. With V941 halted, the landscape is clear... -
Pharma & Biotech News
UK Series (Final): Case Studies: Execution from the UK in Practice (3–5 Short Cases)
Executive Summary|This collection grounds Parts 1–4 in practice: a rare-disease PoC, a multi-ancestry stratified trial, access optimization, manufacturing × capital structuring, and a repurposing example. Each case includes a ready-to-u... -
Pharma & Biotech News
UK Series (Part 4): Execution from the UK: Trials, Access, and Manufacturing Playbooks
Executive Summary|This playbook turns designs into action. By running regulation (MHRA), access (NICE), manufacturing, and commercial readiness in parallel, teams can compress time-to-market. We outline UK-led PoC timelines, parallel re... -
Pharma & Biotech News
UK Series (Part 3): From Genomes to Targets: Biomarkers, Stratification, and Repurposing at Scale
Executive Summary|UK-scale WGS and multi-ancestry GWAS enable earlier, stronger target validation, biomarker design, indication shaping, and safety anticipation. This article turns discoveries into practice—workflows, metrics, QC, and p... -
Pharma & Biotech News
UK Series (Part 2): Data-Driven UK: How WGS and Multi-Ancestry GWAS Rewire Drug Discovery
Executive Summary|The UK’s edge lies in its public data infrastructure. With ~490k whole-genome sequences (WGS) extending into non-coding, rare variants, and structural variation—and a multi-ancestry GWAS program (Pan-UK Biobank)—the ec... -
Pharma & Biotech News
UK Series (Part 1): The UK Life Sciences Strategy: Policy, Regulation, and Investment at Full Tilt
Executive Summary|The UK’s 2025 industrial strategy update places life sciences among its priority sectors, aiming to become Europe’s No.1 by 2030 and the world’s No.3 by 2035. In lockstep with the NHS long-term roadmap, the plan combin... -
Oncology FDA Approval
Oncology Drug Approval News Flash: FDA Approves Lurbinectedin Plus Atezolizumab for Maintenance in Extensive-Stage Small Cell Lung Cancer
On October 2, 2025, the U.S. Food and Drug Administration (FDA) approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals) in combination with atezolizumab (Tecentriq, Genentech) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) fo... -
Pharma & Biotech News
Bonus Track Special: Implications for Japan & Asia — How US “Reallocation” Reshapes Opportunities
Category: Pharma & Biotech NEWS | Special Feature B What you will learn Key TakeawaysContextOptimal US–Japan Scheme (Who Does What)Rights Architecture for East AsiaFour Patterns Key Takeaways Capital follows the cleared path (POC → C... -
Pharma & Biotech News
Bonus Track-Special: Redesigning M&A & Partnerships — From Overlap Removal to “Rights Architecture”
Category: Pharma & Biotech NEWS | Special Feature A What you will learn Key TakeawaysWhy Redesign NowPMI Playbook: Lock Value in 90 DaysThe “Rights Architecture” BlueprintFour Execution Patterns Key Takeaways PMI defines value: 80% o... -
Pharma & Biotech News
Series “Reading 2025 Layoffs” — Final: Practical Playbook: Checklists and Capital Strategy for Founders & Investors (Part 5)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 5 (Final) What you will learn Key TakeawaysPurposeFor Founders|Script the Capital PlanFounder ChecklistFor Investors|Diligence “Triad” Key Takeaways Event-synce... -
Pharma & Biotech News
Series “Reading 2025 Layoffs”: The Funding Climate: How Selectivity Works Across VC, Public, Debt, and M&A (Part 4)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 4 What you will learn Key TakeawaysPurposeVenture Capital: Deeper SelectivityPublic Markets (IPO/Follow-ons): Proof × SupplyDebt (Venture Debt/Convertibles): The ... -
Pharma & Biotech News
Series “Reading 2025 Layoffs”: Modality-by-Modality: Manufacturing, Regulatory, and Commercial Realities (Part 3)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 3 What you will learn Key TakeawaysPurposeCell Therapies (Autologous/Allogeneic CAR-T, TIL)Gene Therapy/Editing (AAV, LNP, CRISPR/Base Editing)mRNA (Post-COVID Op... -
Pharma & Biotech News
Series “Reading 2025 Layoffs”: Reshaping by Disease Areas: From Oncology to Neuroscience (Part 2)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 2 Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 2 What you will learn Key TakeawaysPurposeOncology (Solid & Hematologic)Neuroscie... -
Pharma & Biotech News
Series “Reading 2025 Layoffs”: 2025 Biotech/Pharma Layoffs at a Glance: What Happened and Where It Concentrated (Part 1)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 1 What you will learn Key TakeawaysPurpose & Scope2025 SnapshotPatterns by Company SizeWhy It Happened: Five Drivers Key Takeaways Selectivity & Focus: La... -
Oncology FDA Approval
Oncology Drug Approval News Flash: FDA Approves Imlunestrant (Inluriyo) for ER-Positive, HER2-Negative, ESR1-Mutated Breast Cancer
On September 25, 2025, the U.S. Food and Drug Administration (FDA) approved Eli Lilly’s estrogen receptor antagonist Imlunestrant (Inluriyo) for the treatment of adult patients with ER-positive, HER2-negative, ESR1-mutated advanced or me... -
AI Drug Discovery
Using Microbial Signatures the Right Way: QC, Statistics, Deployment, and Atlas Roadmap (Part 2 | For Experts)
Building on Part 1, this expert-oriented post distills practical guidance from the recent TCGA re-analysis and the Genomics England WGS study. The core message is realistic but enabling: robust microbial signatures exist, but in limited ... -
Science News
Rethinking Cancer Atlases and “Microbial Signatures”: History, Importance, and the Latest Update (Part 1 | Intro for Beginners)
This post explains, in plain language, why pan-cancer (comprehensive) analyses and atlas databases matter in oncology, and how the concept of microbial signatures fits into that bigger picture. As a short preface to the series, we also t...